Diagnosis and Treatment of Drug Overdose

  • Margaret M. McCarron

Abstract

Interest in drug overdosage has changed in recent years, because of the extension of drug abuse to all segments of society, the advent of new drugs with specific new actions, the widespread availability of serum drug concentrations, and the emphasis being placed on toxicology by the relatively new field of Emergency Medicine. Misuse of new therapeutic agents has resulted in new types of overdoses requiring new treatments. Since most overdoses are not life threatening, good results may be obtained in many cases without making a diagnosis. However, severe and unusual cases necessitate specific diagnosis and treatment. Toxicology results have shown that mistakes occur when the diagnosis is made on clinical grounds only. Establishing a preliminary diagnosis and providing rational therapy requires a working knowledge of clinical pharmacology, including specific information about the actions of the various drugs, their important chemical and kinetic properties, and their toxic manifestations.

Keywords

Phenanthrene Dobutamine Isoniazid Toxicology Dopa 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reed CE, Driggs MF, Foote CC: Acute barbiturate intoxication: a study of 300 cases based on a physiologic system of classification of the severity of the intoxication. Ann Intern Med 37: 290, 1954.Google Scholar
  2. 2.
    Matthew H, Lawson A AH: Acute barbiturate poisoning—a review of two years’ experience. Q J Med 35: 539–552, 1966.Google Scholar
  3. 3.
    Teasdale G, Jennett B: Assessment of coma and impaired consciousness—a practical scale. Lancet 2: 81–84, 1974.PubMedGoogle Scholar
  4. 4.
    McCarron MM, Schulze BW, Walberg CB, Thompson GA, Ansari A: Short-acting barbiturate overdosage—correlation of intoxication score with serum barbiturate concentration. JAMA 248: 55–61, 1982.PubMedGoogle Scholar
  5. 5.
    Simpson D, Reilly P: Paediatric coma scale. Lancet 2: 450, 1982.PubMedGoogle Scholar
  6. 6.
    Tandberg D, Sklar D: Effect of tachypnea on the estimation of body temperature by an oral thermometer. N Engl J Med 308: 945–946, 1983.PubMedGoogle Scholar
  7. 7.
    Goldfrank L, Osborn H: Rainbow urine. Hosp Pract 3: 22–26, 1978.Google Scholar
  8. 8.
    Lewis JM, Klein-Schwartz W, Benson BE, et al.: Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 138: 944–946, 1984.PubMedGoogle Scholar
  9. 9.
    Greenberg MI, Roberts JR, Baskin SI: Endotracheal naloxone reversal of morphine-induced respiratory depression in rabbits. Ann Emerg Med 9: 289–292, 1980.PubMedGoogle Scholar
  10. 10.
    Tandberg D, Abercrombie D: Treatment of heroin overdose with endotracheal naloxone. Ann Emerg Med 11: 443–445, 1982.PubMedGoogle Scholar
  11. 11.
    Chen HL: Naloxone in shock and toxic coma. Am J Emerg Med 2: 444–452, 1984.PubMedGoogle Scholar
  12. 12.
    Andree RA: Sudden death following naloxone administration. Anesth Analg 59: 782–784, 1980.PubMedGoogle Scholar
  13. 13.
    Azar I, Turndorf H: Severe hypertension and mul¬tiple atrial premature contractions following naloxone administration. Anesth Analg 58: 524–525, 1979.PubMedGoogle Scholar
  14. 14.
    Tanaka GY: Hypertensive reaction to naloxone. JAMA 228: 25–26, 1974.PubMedGoogle Scholar
  15. 15.
    Michaelis LL, Hickey PR, Clark TA, et al.: Ventricular irritability associated with the use of naloxone. Ann Thorac Surg 18: 608–614, 1974.PubMedGoogle Scholar
  16. 16.
    Mannelli M, Maggi M, DeFeo ML, et al.: Naloxone administration releases catecholamines. New Engl J Med 308: 654–655, 1983.PubMedGoogle Scholar
  17. 17.
    Slovin CM, Bachvarov HL: Heated inhalation treatment of hypothermia. Am J Emerg Med 2: 533–536, 1984.Google Scholar
  18. 18.
    McCarron MM: The use of toxicology tests in emergency room diagnosis. J Analyt Toxicol 7: 131–135, 1983.Google Scholar
  19. 19.
    Beveridge GW, Lawson AAH: Occurrence of bullous lesions in acute barbiturate intoxication. Br Med J 1: 835–837, 1965.PubMedGoogle Scholar
  20. 20.
    Mandy S, Akerman AB: Characteristic traumatic skin lesions in drug-induced coma. JAMA 213: 253–256, 1970.PubMedGoogle Scholar
  21. 21.
    Schanker LS: Absorption of drugs from the rat colon. J Pharmacol Exp Ther 126: 282, 1959.Google Scholar
  22. 22.
    Mark LC: Pharmacokinetics of barbiturates. In Matthew H (ed): Acute Barbiturate Poisoning. Excepta Medica, Amsterdam, pp 75–83, 1971.Google Scholar
  23. 23.
    Study RE, Barker JL: Cellular mechanisms of benzodiazepine action. JAMA 247: 2147–2151, 1982.PubMedGoogle Scholar
  24. 24.
    Walberg CB: An ultraviolet spectrophotometric procedure for differentiating and quantitation of barbiturates. Clin Toxicol 18: 879–885, 1981.PubMedGoogle Scholar
  25. 25.
    Berg MJ, Berlinger WG, Goldberg MJ, et al.: Acceleration of the body clearance of phénobarbital by oral activated charcoal. N Engl J Med 307: 642–644, 1982.PubMedGoogle Scholar
  26. 26.
    King K, England JF: Chloral hydrate (Noctec) overdose. Med J Austral 6: 260, 1983.Google Scholar
  27. 27.
    Information from manufacturer, Squibb Company, 1984.Google Scholar
  28. 28.
    Gleich GJ, Mongan ES, Vaules DW: Esophageal stricture following chloral hydrate poisoning. JAMA 201: 266–267, 1967.PubMedGoogle Scholar
  29. 29.
    Stalker NE, Gambertoglio JG, Fukumitsu CJ, et al.: Acute massive chloral hydrate intoxication treated with hemodialysis: a clinical pharmacokinetic analysis. J Clin Pharmacol 18: 136–142, 1978.PubMedGoogle Scholar
  30. 30.
    Marshall AJ: Cardiac arrhythmias caused by chloral hydrate. Br Med J 2: 994, 1977.PubMedGoogle Scholar
  31. 31.
    Gustafson A, Svensson SE, Ugander L: Cardiac arrhythmias in chloral hydrate poisoning. Acta Med Scand 201: 227–230, 1977.PubMedGoogle Scholar
  32. 32.
    Vellar IDA, Richardson JP, Doyle JC, Keating M: Gastric necrosis: a rare complication of chloral hydrate intoxication. Br J Surg 59: 317–319, 1972.Google Scholar
  33. 33.
    Health A, Delin K, Eden E, et al.: Hemoperfusion with Amberlite resin in the treatment of self-poi- soning. Acta Med Scand 207: 455, 1980.Google Scholar
  34. 34.
    Baselt RC: Disposition of toxic drugs and chemicals in man, 2nd ed. Biomedical Publications, Davis, California, 1982.Google Scholar
  35. 35.
    Information from manufacturer, Abbott Company, 1984.Google Scholar
  36. 36.
    Fairman RP, Glauser FL, Falls R: Increases in lung lymph and albumin clearance with ethchlorvynol. J Appl Physiol 50: 1151–1155, 1981.PubMedGoogle Scholar
  37. 37.
    Glauser FL, Smith WR, Caldwell A, et al.: The effects of ethchlorvynol on pulmonary alveolar membrane permeability. Am Rev Resp Dis 116: 901–906, 1977.PubMedGoogle Scholar
  38. 38.
    Van Swearingen P: Placidyl and pulmonary edema. Ann Intern Med 84: 614–615, 1976.PubMedGoogle Scholar
  39. 39.
    Rosenthal R, Brown JM: Placidyl and pulmonary effects. Ann Intern Med 85: 126, 1976.PubMedGoogle Scholar
  40. 40.
    Self TM, Fountain FF, Dunnebacke R, et al.: Intravenous ethchlorvynol-induced pulmonary edema. Drug Intell Clin Pharm 13: 96–99, 1979.Google Scholar
  41. 41.
    Burton WN, Vender J, Shapiro BA: Adult respiratory distress syndrome after placidyl abuse. Crit Care Med 8: 48–49, 1980.PubMedGoogle Scholar
  42. 42.
    Klock JC: Hemolysis and pancytopenia in eth¬chlorvynol overdose. Ann Intern Med 81: 131–132, 1974.PubMedGoogle Scholar
  43. 43.
    Brodin MB, Redmond WJ: Bullous eruption due to ethchlorvynol. J Cutan Path 7: 326–329, 1980.PubMedGoogle Scholar
  44. 44.
    Lynn RI, Honig CL, Jatlow PI, Kliger AS: Resin hemoperfusion for treatment of ethchlorvynol overdose. Ann Intern Med 91: 549–553, 1979.PubMedGoogle Scholar
  45. 45.
    Benowitz N, Abolin C, Toxer T, et al.: Resin hemoperfusion in ethchlorvynol overdose. Clin Pharmacol Ther 27: 236–242, 1980.PubMedGoogle Scholar
  46. 46.
    Hammond KB, Rumack BH, Rodgerson DE: Blood ethanol. JAMA 226: 63–64, 1973.PubMedGoogle Scholar
  47. 47.
    Bogusz M, Peck J, Stasko W: Comparative studies on the rate of ethanol elimination in acute poisoning and in controlled conditions. J For Sci 22: 446–451, 1977.Google Scholar
  48. 48.
    Goodman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, 1980.Google Scholar
  49. 49.
    Jeffries DB, Flanagan RJ, Volans GN: Reversal of ethanol-induced coma with naloxone. Lancet 1: 308–309, 1980.Google Scholar
  50. 50.
    Shramek JJ: Loads [Letter]. N Engl J Med 305: 231, 1982.Google Scholar
  51. 51.
    Hansen AR, Kennedy KA, Ambre JJ, Fischer LJ: Glutethimide poisoning. A metabolite contributes to morbidity and mortality. N Engl J Med 292: 250, 1975.PubMedGoogle Scholar
  52. 52.
    Rosenbaum JL, Kramer MS, Raja R: Resin hemoperfusion for acute drug intoxication. Arch Intern Med 136: 263, 1976.PubMedGoogle Scholar
  53. 53.
    Rotschafer JC, Foleyh C, Zaske D: Glutethimide overdose: clinical and kinetic observations of glutethimide and a metabolite. Minn Med 63: 145–147, 1980.PubMedGoogle Scholar
  54. 54.
    Baselt RC, Cravey RH: A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids. J Analyt Toxicol 1: 81–103, 1977.Google Scholar
  55. 55.
    Information from manufacturer, Wyeth Company, 1984.Google Scholar
  56. 56.
    Blumberg AG, Rosett GHL, Dobrow A: Severe hypotensive reactions following meprobamate overdosage. Ann Intern Med 51: 607, 1959.PubMedGoogle Scholar
  57. 57.
    Scott PAL, Grimshaw L, Molony HMP: Severe hypotensive crisis following treatment with meprobamate. Arch Intern Med 100: 484–486, 1957.Google Scholar
  58. 58.
    Jenis EH, Payne RJ, Goldbaum LR: Acute mepro¬bamate poisoning. A fatal case following a lucid interval. JAMA 207: 361–362, 1969.PubMedGoogle Scholar
  59. 59.
    Schwartz HS: Acute meprobamate poisoning with gastrotomy and removal of drug-containing mass. N Engl J Med 295: 1177–1178, 1976.PubMedGoogle Scholar
  60. 60.
    Dyment PC, Curtis DD, Gourich GE: Meprobamate poisoning treated with peritoneal dialysis. J Ped 67: 124, 1965.Google Scholar
  61. 61.
    Maddock RK, Bloomer HA: Meprobamate over¬dosage. Evaluation of its severity and methods of treatment. JAMA 201: 999–1003, 1967.PubMedGoogle Scholar
  62. 62.
    Hoy WE, Rivero A, Marin MG, Rieders F: Resin hemoperfusion for treatment of massive meprobamate overdose. Ann Intern Med 93: 455–456, 1980.PubMedGoogle Scholar
  63. 63.
    WHO Review Group: Use and abuse of benzodiazepines. Bull World Health Organization 61: 551–562, 1983.Google Scholar
  64. 64.
    Hayes SL, Pablo G, Radomski T, Palmer RF: Ethanol and oral diazepam absorption. N Engl J Med 296: 186, 1977.PubMedGoogle Scholar
  65. 65.
    Ninan PT, Insel TM, Cohen RM, et al.: Benzodiazepine receptor-mediated experimental “anxiety” in primates. Science 218: 1332–1334, 1982.PubMedGoogle Scholar
  66. 66.
    Petursson H, Lader MH: Withdrawal from long- term benzodiazepine treatment. Br Med J 283: 643–645, 1981.Google Scholar
  67. 67.
    Finkle BS, McCloskey KL, Goodman LS: Diazepam and drug-associated deaths. JAMA 242: 429–434, 1979.PubMedGoogle Scholar
  68. 68.
    Avant GR, Speeg KV, Freemon FR, Schenker S, Berman ML: Physostigmine reversal of diazepam-induced hypnosis: a study in human volunteers. Ann Intern Med 91: 53–55, 1979.PubMedGoogle Scholar
  69. 69.
    Darragh A, Lambe R, Brick I: Reversal of benzodiazepine-induced sedation by intravenous Ro 15–1788. Lancet 2: 1042, 1981.PubMedGoogle Scholar
  70. 70.
    Information from manufacturer, Roche Company, 1984.Google Scholar
  71. 71.
    Lion JR, Azcarate CL, Koepke HH: “Paradoxical rage reactions” during psychotropic medication. Dis Nerv Syst 36: 557–558, 1975.PubMedGoogle Scholar
  72. 72.
    Karch FE: Rage reaction associated with clorazepate dipotassium. Ann Intern Med 81: 61–62, 1979.Google Scholar
  73. 73.
    McBay AJ: Chemical findings in poisonings. N Engl J Med 274: 1257, 1966.PubMedGoogle Scholar
  74. 74.
    Cate JC, Jatlow PI: Chlordiazepoxide overdose: interpretation of serum drug concentrations. Clin Toxicol 6: 553–561, 1973.Google Scholar
  75. 75.
    Hollister LE, Montzenbecker FP, Degan RL: Withdrawal reactions from chlordiazepoxide (Librium). Psychopharmacology 2: 63, 1961.Google Scholar
  76. 76.
    Richman S, Harris RD: Acute pulmonary edema associated with Librium abuse. Radiology 103: 57–58, 1972.PubMedGoogle Scholar
  77. 77.
    Browne TR: Clonazepam. New Engl J Med 299: 812–816, 1978.PubMedGoogle Scholar
  78. 78.
    Welch TR, Rumack BH, Hammond K: Clonazepam overdose resulting in cyclic coma. Clin Toxicol 10: 433–436, 1977.PubMedGoogle Scholar
  79. 79.
    Barnett AM: Treatment of epilepsy with clonazepam (Ro 5-4023). South Afr Med J 47: 1683–1686, 1973.Google Scholar
  80. 80.
    Bladin PF: The use of clonazepam as an anticonvulsant: clinical evaluation. Med J Austral 1: 683–688, 1973.PubMedGoogle Scholar
  81. 81.
    Edwards VE, Eadie MJ: Clonazepam: a clinical study of its effectiveness as an anticonvulsant. Proc Austral Assoc Neurol 10: 61–66, 1973.Google Scholar
  82. 82.
    Pach VD: The dangers of diazepam, a street drug. New Engl J Med 290: 807, 1974.Google Scholar
  83. 83.
    Divoli M, Greenblatt DJ, Lacasse Y, Shader RI: Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacology 73: 381–383, 1981.Google Scholar
  84. 84.
    Cowan PJ, Nutt DJ: Abstinense symptoms after withdrawal of tranquilizing drugs: is there a common mechanism? Lancet 2: 360–362, 1982.Google Scholar
  85. 85.
    Baselt RC, Cravey RH: A compendium of therapeutic and toxic concentrations of toxicologically significant drugs in human biofluids. J Analyt Toxicol 1: 81–103, 1977.Google Scholar
  86. 86.
    Aderjan R, Mattern R: Eine toedlich verlaufene monintoxikation mit flurazepam (Dalmadorm). Arch Toxicol 43: 69–75, 1979.PubMedGoogle Scholar
  87. 87.
    Ferrara SD, Tedeschi L, Marigo M, Castagna F: Concentrations of phenobarbital, flurazepam, and flurazepam metabolites in autopsy cases. J For Sci 24: 61–69, 1979.Google Scholar
  88. 88.
    Ruff RL, Kutt H, Hafler D: Prolonged benzodiazepine coma. NY State J Med 81: 776–777, 1981.Google Scholar
  89. 89.
    Leppik IE, Derivan AT, Homan RW, et al.: Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249: 1452–1454, 1983.PubMedGoogle Scholar
  90. 90.
    Allen MD, Greenblatt DJ, Lacasse Y, Shader RI: Pharmacokinetic study of lorazepam overdosage. Am J Psychiatr 137: 1414–1415, 1980.PubMedGoogle Scholar
  91. 91.
    Jeffrey DI, Whitfield MF: Lorazepam poisoning. Br Med J 4: 719, 1974.Google Scholar
  92. 92.
    Vlachos P, Kentarchou P, Poulos L, Aloupogiannis G: Lorazepam poisoning. Tox Lett 2: 109–110, 1978.Google Scholar
  93. 93.
    Matthew H, Proudfoot AT, Aitken RCB, et al.: Nitrazepam—a safe hypnotic. Br Med J 3: 23–25, 1969.PubMedGoogle Scholar
  94. 94.
    Adelstein AM: Safety of nitrazepam [Letter]. Lancet 1: 933–934, 1974.PubMedGoogle Scholar
  95. 95.
    Oliver JS, Smith H: Determination of nitrazepam in poisoning cases. For Sci 4: 183–186, 1974.Google Scholar
  96. 96.
    Torry JM: A case of suicide with nitrazepam and alcohol. Practitioner 217: 648–649, 1976.PubMedGoogle Scholar
  97. 97.
    Bardhan KD: Cerebellar syndrome after nitrazepam overdosage. Lancet 1: 1319–1320, 1969.PubMedGoogle Scholar
  98. 98.
    Shimkin PM, Shaivitz SA: Oxazepam poisoning in a child. JAMA 196: 662–663, 1966.PubMedGoogle Scholar
  99. 99.
    Zileli MMS, Teletar F, Deniz S, et al.: Oxazepam intoxication simulating non-keto-acidotic diabetic coma. JAMA 215: 1986, 1971.Google Scholar
  100. 100.
    Product information, Upjohn Company, 1982.Google Scholar
  101. 101.
    Trappier B, Bezeredi T: Triazolam intoxication. Can Med Assoc J 126: 893–894, 1982.Google Scholar
  102. 102.
    Martin FIR, Hansen N, Warn GL: Attempted suicide by insulin overdose in insulin requiring diabetics. Med J Austral 1: 58–60, 1977.PubMedGoogle Scholar
  103. 103.
    Sturner WQ, Putnam RS: Suicidal insulin poisoning with nine day survival: recovery in bile at autopsy by radioimmunossay. J For Sci 9: 37–42, 1977.Google Scholar
  104. 104.
    Brikinshaw VJ, Gurd MR, Randall SS, et al.: Investigations in a case of murder by insulin poisoning. Br Med J 2: 463–468, 1958.Google Scholar
  105. 105.
    Bauman WA, Yalow RS: Insulin as a lethal weapon. J For Sci 26: 594–598, 1981.Google Scholar
  106. 106.
    Bobzien WF: Suicidal overdoses with hypoglycemic agents. J Coll Emer Phy 8: 467–470, 1979.Google Scholar
  107. 107.
    Seltzer HS: Drug-induced hypoglycemia-a review based on 473 cases. Diabetes 21: 955–966, 1972.PubMedGoogle Scholar
  108. 108.
    Alexander RW: Prolonged hypoglycemia following acetohexamine administration. Diabetes 15: 362, 1966.PubMedGoogle Scholar
  109. 109.
    Dougherty, J: Hypoglycemic stupor caused by acetohexamide. N Engl J Med 274: 1256–1258, 1966.PubMedGoogle Scholar
  110. 110.
    Cowen DL, Burtis B, Youmans J: Prolonged coma after acetohexamide ingestion. JAMA 201: 155–156, 1967.Google Scholar
  111. 111.
    Lampe WT: Hypoglycemia due to acetohexamide. Arch Intern Med 120: 239–241, 1967.PubMedGoogle Scholar
  112. 112.
    Skoutakis VA, Black WD, Acchiardo SR, Wood GC: Peritoneal dialysis in the treatment of acetohexamide-induced hypoglycemia. Am J Hosp Pharm 34: 68–70, 1977.PubMedGoogle Scholar
  113. 113.
    Agarwal RC, Kumar D, Miller LV: Chlorpropamide-induced hypoglycemia. Diabetes 19: 376, 1970.Google Scholar
  114. 114.
    Levin EB: Severe hypoglycemic reaction with chlorpropamide in therapeutic dosage. Calif Med 98: 279, 1963.PubMedGoogle Scholar
  115. 115.
    Sackner MA, Balian LJ: Permanent brain damage secondary to the ingestion of chlorpropamide. Am J Med 28: 125, 1960.Google Scholar
  116. 116.
    Graw RG: Chlorpropamide intoxication—treatment with peritoneal dialysis. Pediatrics 45: 106–109, 1970.PubMedGoogle Scholar
  117. 117.
    Dowell RC, Imrie AH: Chlorpropamide poisoning in non-diabetics. Scot Med J 17: 305–309, 1972.PubMedGoogle Scholar
  118. 118.
    Johnson SF, Schade DS, Peake GT: Chlorproamide-induced hypoglycemia. Am J Med 63: 799–804, 1977.PubMedGoogle Scholar
  119. 119.
    Sillence DO, Court JM: Glibenclamide-induced hypoglycemia. Br Med J 3: 490–491, 1975.PubMedGoogle Scholar
  120. 120.
    Pavone L, Mollica F, Mususemici S, et al.: Accidental glibenclamide ingestion in an infant: clinical and encephalographic aspects. Dev Med Child Neurol 22: 366–371, 1980.PubMedGoogle Scholar
  121. 121.
    Kullavanijaya P: Recovery from overdose of glibenclamide. Br Med J 4: 53–54, 1970.PubMedGoogle Scholar
  122. 122.
    Ahlquist DA, Nelson RL, Callaway CW: Pseudoinsulinoma syndrome from inadvertent tolazamide ingestion. Ann Intern Med 93: 281–282, 1980.PubMedGoogle Scholar
  123. 123.
    Cosnett JE: Tolbutamide overdosage and irreversible cerebral damage. South Afr Med J 35: 43–44, 1961.Google Scholar
  124. 124.
    Forrest JAH: Clorpropamide overdosage: delayed and prolonged hypoglycemia. Clin Toxicol 7: 19–24, 1974.PubMedGoogle Scholar
  125. 125.
    Mari G, Cozzolino G, Palumbo R: Glucagon in sulfonylurea hypoglycemia. Lancet 1: 303, 1968.Google Scholar
  126. 126.
    Altszuler N, Hampshire J, Morarv E: On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26: 931–935, 1977.PubMedGoogle Scholar
  127. 127.
    Balsam MJ, Baker L, Bishop HC, et al.: Beta cell adenoma in a child with hypoglycemia controlled with diazoxide. J Ped 80: 788–795, 1972.Google Scholar
  128. 128.
    Pert CB, Snyder SH: Opiate receptor: demonstration in nervous tissue. Science 179: 1011–1014, 1973.PubMedGoogle Scholar
  129. 129.
    Martin WR: Naloxone. Ann Intern Med 85: 765–768, 1976.PubMedGoogle Scholar
  130. 130.
    Jaffe JH, Martin WR: Opioid analgesics and antagonists, Chapter 22. In Goodman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, pp 494–534, 1980.Google Scholar
  131. 131.
    Gilbert PE, Martin WR: Antagonism of the convulsant effects of heroin, d-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice. J Pharmacol Exp Ther 192: 538–541, 1975.PubMedGoogle Scholar
  132. 132.
    Snyder SH, Pert CB, Pasternak GW. The opiate receptor. Ann Intern Med 81: 534–540, 1974.PubMedGoogle Scholar
  133. 133.
    Jhamandas K, Phillis JW, Pinsky C: Effects of narcotic analgesics and antagonists on the in vivo release of acetylcholine from cerebral cortex of the cat. Br J Pharmacol 43: 53–66, 1971.PubMedGoogle Scholar
  134. 134.
    Snyder SH: The opiate receptor and morphine-like peptides in the brain. Am J Psychiatr 135: 645–652, 1978.PubMedGoogle Scholar
  135. 135.
    Sharma SK, Klee WA, Nirenberg M: Dual regulation of adenyl cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci 72: 3092–3096, 1975.PubMedGoogle Scholar
  136. 136.
    Florez J, McCarthy LE, Borison HL: A comparative study in the cat of the respiratory effects of morphine injected intravenously and into the cerebrospinal fluid. J Pharmacol Exp Ther 163: 448–455, 1968.PubMedGoogle Scholar
  137. 137.
    Eckenhoff JE, Oesch SR: The effects of narcotics and antagonists upon respiration and circulation in man. Clin Pharm Ther 1: 483–524, 1960.Google Scholar
  138. 138.
    Tommisto T, Jaattela A, Nikki P, Takki S: Effect of pentazocine and pethidine on plasma catecholamine levels. Ann Clin Res 3: 22–29, 1971.Google Scholar
  139. 139.
    Labi M: Paroxysmal atrial fibrillation in heroin intoxication. Ann Intern Med 71: 951–959, 1969.PubMedGoogle Scholar
  140. 140.
    Abramson DH: Bigeminy and heroin intoxication. NY State J Med 72: 2888–2890, 1972.Google Scholar
  141. 141.
    Lee HK, Wang SC: Mechanism of morphine induced miosis in the dog. J Pharmacol Exp Ther 192: 415–431, 1975.Google Scholar
  142. 142.
    Muhlendahl KE, Krienke EG, Scherf-Rahne B, Baukloh G: Codeine intoxication in childhood. Lancet 2: 303–305, 1976.Google Scholar
  143. 143.
    Rupreht J, Dwaracek B, Oosthoek H, Dzoljic MR, Valkenburg M: Physostigmine versus naloxone in heroin overdose. Clin Toxicol 21: 387–397, 1984.Google Scholar
  144. 144.
    Riding JE, Robinson JS: The safety of neostigmine. Anaesthesia 16: 346–354, 1961.PubMedGoogle Scholar
  145. 145.
    Klock JC, Sexton MJ: Rhabdomyolysis and acute myoglobinuric renal failure following heroin use. Calif Med 119: 5–8, 1973.PubMedGoogle Scholar
  146. 146.
    Schwartzfarb L, Singh G, Marcus D: Heroin-associated rhabdomyolysis with cardiac involvement. Arch Intern Med 137: 1255–1257, 1977.PubMedGoogle Scholar
  147. 147.
    Katz S, Aberman A, Frand UI, et al.: Heroin pulmonary edema, evidence for increased capillary permeability. Am Rev Resp Dis 106: 472–474, 1972.PubMedGoogle Scholar
  148. 148.
    Steinberg AD, Karliner JS: The clinical spectrum of heroin pulmonary edema. Arch Intern Med 122: 122–127, 1968.PubMedGoogle Scholar
  149. 149.
    Berry YJ: Cough-medicine “highs.” N Engl J Med 295: 286–287, 1976.PubMedGoogle Scholar
  150. 150.
    Dunne JW: Drug smuggling by internal bodily concealment. Med J Austral 2: 436–439, 1983.PubMedGoogle Scholar
  151. 151.
    Paranthanan SK, Kahn F: Acute cardiomyopathy with recurrent pulmonary edema and hypotension following heroin overdosage. Chest 69: 117–119, 1976.Google Scholar
  152. 152.
    Baselt RC, Allison DJ, Wright JA, et al.: Acute heroin fatalities in San Francisco—demographic and toxicologic characteristics. West J Med 122: 455–458, 1975.PubMedGoogle Scholar
  153. 153.
    Huber DH, Stiver RR, Howard LB: Heroin-over- dose deaths in Atlanta. JAMA 228: 319–322, 1974.PubMedGoogle Scholar
  154. 154.
    Richards RG, Reed D, Cravey RH: Death from intravenously administered narcotics: a study of 114 cases. J For Sci 21: 467–482, 1976.Google Scholar
  155. 155.
    Duberstein JL, Kaufman DM: A clinical study of an epidemic of heroin intoxication and heroin- induced pulmonary edema. Am J Med 51: 704–714, 1971.PubMedGoogle Scholar
  156. 156.
    Nakamura GR, Griesemer EC, Noguchi TT: Antemortem conversion of codeine to morphine in man. J For Sci 21: 518–524, 1976.Google Scholar
  157. 157.
    Sklar J, Timms RM: Codeine-induced pulmonary edema. Chest 72: 230–231, 1977.PubMedGoogle Scholar
  158. 158.
    Huffman DH, Ferguson RL: Acute codeine overdose: correspondence between clinical course and codeine metabolism. Johns Hopkins Med J 136: 183–186, 1975.PubMedGoogle Scholar
  159. 159.
    Wright JA, Baselt RC Hine CH. Blood codeine concentrations in fatalities associated with codeine. Clin Toxicol 8: 457–463, 1975.PubMedGoogle Scholar
  160. 160.
    Peat MA, Sengupta S: Toxicological investigations of cases of death involving codeine and dihydrocodeine. For Sci 9: 21–32, 1977.Google Scholar
  161. 161.
    Person MA, Poklis A, Morrison RR: A fatality due to the ingestion of (methyl morphine) codeine. Clin Toxicol 15: 267–271, 1979.Google Scholar
  162. 162.
    Inturrisi CE, Verebely K: Disposition of methadone in man after a single oral dose. Clin Pharm Ther 13: 923–930, 1972.Google Scholar
  163. 163.
    Inturrisi CE, Verebely K: The levels of methadone in the plasma in methadone maintenance. Clin Pharm Ther 13: 633–637, 1972.Google Scholar
  164. 164.
    Olsen GD: Methadone binding to human plasma protein. Clin Pharm Ther 14: 338–343, 1973.Google Scholar
  165. 165.
    Aronow R, Brenner SL, Wooley PV: An apparent • epidemic: methadone poisoning in children. Clin Toxicol 6: 175–182, 1973.PubMedGoogle Scholar
  166. 166.
    Smialek JE, Monforte JR, Aronow R, Spitz WU: Methadone deaths in children. JAMA 238: 2516–2517, 1977.PubMedGoogle Scholar
  167. 167.
    Garriott JC, Sturner WQ, Mason MF: Toxicologic findings in six fatalities involving methadone. Clin Toxicol 6: 163–173, 1973.PubMedGoogle Scholar
  168. 168.
    Greene MH, Luke JL, DuPont RL: Opiate overdose deaths in the District of Columbia. Part II. Methadone-related fatalities. J For Sci 19: 575–584, 1974.Google Scholar
  169. 169.
    Waldron VD, Klimt CR, Seibel JE: Methadone overdose treated with naloxone infusion. JAMA 225: 53, 1973.PubMedGoogle Scholar
  170. 170.
    Gram LF, Schou J, Way WL, et al.: d-Propoxyphene kinetics after single oral and intravenous doses in man. Clin Pharm Ther 26: 473–482, 1979.Google Scholar
  171. 171.
    McMahon RE, Ridolfo AS, Culp HW, et al.: The fate of radiocarbon-labelled propoxyphene in rat, dog, and human. Tox Appl Pharm 19: 427–444, 1971.Google Scholar
  172. 172.
    Qureshi E: Propoxyphene hydrochloride poisoning. JAMA 185: 470–471, 1964.Google Scholar
  173. 173.
    Heaney RM: Left bundle branch block associated with propoxyphene hydrochloride poisoning. Ann Emerg Med 12: 780–782, 1983.PubMedGoogle Scholar
  174. 174.
    Gustafson A, Gustafson B: Acute poisoning with dextropropoxyphene. Acta Med Scand 200: 241–248, 1976.PubMedGoogle Scholar
  175. 175.
    Fisch HP, Wands J, Yeung J, Davis PJ: Pulmonary edema and disseminated intravascular coagulation after intravenous abuse of d-propoxyphene (Darvon). South Med J 65: 493–495, 1972.PubMedGoogle Scholar
  176. 176.
    Young DJ: Propoxyphene suicides—report of nine cases. Arch Intern Med 129: 62–66, 1972.PubMedGoogle Scholar
  177. 177.
    Sturner WQ, Garriott JC: Deaths involving pro-poxyphene. A study of 41 cases over a two-year period. JAMA 223: 1125–1130, 1973.PubMedGoogle Scholar
  178. 178.
    Szeto HH, Inturrisi CE, Houde R, et al.: Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure and cancer. Ann Intern Med 86: 738–741, 1977.PubMedGoogle Scholar
  179. 179.
    Siek TJ: The analysis of meperidine and normeperidine in biological specimens. J For Sci 23: 6–13, 1978.Google Scholar
  180. 180.
    Information from manufacturer, Winthrop Company, 1984.Google Scholar
  181. 181.
    Ford GC, Haskins NJ, Palmer RF, et al.: The measurement of diphenoxylic acid in plasma following administration of diphenoxylate. Biomed Mass Spec 3: 45–47, 1976.Google Scholar
  182. 182.
    Karim A, Ranney RE, Eversen KL, Clark ML: Pharmacokinetics and metabolism of diphenoxylate in man. Clin Pharm Ther 13: 407–419, 1972.Google Scholar
  183. 183.
    Henderson W, Psaila A: Lomotil poisoning. Lancet 1: 307–308, 1969.PubMedGoogle Scholar
  184. 184.
    Harris JT, Rossiter M: Fatal lomotil poisoning. Lancet: 1: 150, 1969.Google Scholar
  185. 185.
    Rumach BH, Temple AR: Lomotil poisoning. Pediatrics 53: 495–500, 1974.Google Scholar
  186. 186.
    Amment ME: Diphenoxylate poisoning in children. J Ped 74: 462–464, 1969.Google Scholar
  187. 187.
    Riley ID: Lomotil poisoning. Lancet 1: 374, 1969.Google Scholar
  188. 188.
    Curtis JA, Goel KM: Lomotil poisoning in children. Arch Dis Child 54: 222–225, 1979.PubMedGoogle Scholar
  189. 189.
    Information from manufacturer, Searle Company, 1984.Google Scholar
  190. 190.
    Brown JW: Toxic megacolon associated with loperamide therapy. JAMA 241: 501–502, 1979.PubMedGoogle Scholar
  191. 191.
    Information from manufacturer, Janssen Company, 1984.Google Scholar
  192. 192.
    Marcovitch H: Loperamide in toddler diarrhea. Lancet 1: 1413, 1980.PubMedGoogle Scholar
  193. 193.
    Friedli G, Haenggeli CA: Loperamide overdose managed by naloxone. Lancet 1: 1413, 1980.PubMedGoogle Scholar
  194. 194.
    Hunter R, Ingram IM: Intravenous pentazocine abuse by a nurse. Lancet 2: 227, 1983.PubMedGoogle Scholar
  195. 195.
    Stahl SM, Kasser IS: Pentazocine overdose. Ann Emerg Med 12: 28–31, 1983.PubMedGoogle Scholar
  196. 196.
    Showalter CV: T’s and blues—abuse of pentazocine and tripelennamine. JAMA 244: 1224–1225, 1980.PubMedGoogle Scholar
  197. 197.
    DeBard ML, Jagger JA: “T’s and blues”—midwestern heroin substitute. Clin Toxicol 18: 1117–1123, 1981.Google Scholar
  198. 198.
    Butch AJ, Yokel RA, Sigell LT, et al.: Abuse and pulmonary complications of injecting pentazocine and tripelennamine tablets. Clin Toxicol 14: 301–306, 1979.PubMedGoogle Scholar
  199. 199.
    Information from manufacturer, Bristol Company, 1984.Google Scholar
  200. 200.
    Gaver RC, Vasijev M, Wong H, et al.: Disposition of parenteral butorphanol in man. Drug Met Disp 8: 230–235, 1980.Google Scholar
  201. 201.
    Information from manufacturer, Du Pont Company, 1984.Google Scholar
  202. 202.
    Westfall TC: Local regulation of adrenergic transmission. Physiol Rev 57: 659–728, 1977.PubMedGoogle Scholar
  203. 203.
    Goldberg MR, Robertson D: Yohimbine: a pharmacological probe for study of the alpha-2 adrenoceptor. Pharmacolog Rev 35: 143–180, 1983.Google Scholar
  204. 204.
    Hoffman BB, Lefkowitz RJ: Alpha-adrenergic receptor subtypes. New Engl J Med 302: 1390–1391, 1980.PubMedGoogle Scholar
  205. 205.
    McGrath JC: Evidence for more than one type of postjunctional alpha adrenoceptor. Biochem Pharmacol 31: 467–484, 1982.PubMedGoogle Scholar
  206. 206.
    Nwanze E, Jonsson G: Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice [Letter]. Neuroscience 26: 163–168, 1981.Google Scholar
  207. 207.
    Trulson ME, Jacobs BL: Long-term amphetamine treatment decreases brain serotonin metabolism: implications for theories of schizophrenia. Science 205: 1295–1297, 1979.PubMedGoogle Scholar
  208. 208.
    Wagner GC, Ricaurte GA, Johnson CE, Schuster CR, Seiden LS: Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 30: 547–550, 1980.PubMedGoogle Scholar
  209. 209.
    Ginsberg MD, Hertzman M, Schmidt-Nowara WW: Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. Ann Intern Med 73: 81–85, 1970.PubMedGoogle Scholar
  210. 210.
    Harrington H, Heller A, Dawson D, et al.: Inter- cerebral hemorrhage and oral amphetamine. Arch Neurol 40: 503–507, 1983.PubMedGoogle Scholar
  211. 211.
    Delaney P, Estes M: Intracranial hemorrhage with amphetamine abuse. Neurology 30: 1125–1128, 1980.PubMedGoogle Scholar
  212. 212.
    Citron BP, Halpern M, McCarron MM, et al.: Necrotizing angiitis associated with drug abuse. N Engl J Med 283: 1003–1011, 1970.PubMedGoogle Scholar
  213. 213.
    Matick H, Anderson D, Brumlik J: Cerebral vasculitis associated with oral amphetamine overdose. Arch Neurol 40: 253–254, 1983.PubMedGoogle Scholar
  214. 214.
    Eplin DE, Done AK: Amphetamine poisoning, effectiveness of chlorpromazine. N Engl J Med 278: 1361–1365, 1968.Google Scholar
  215. 215.
    Gary NE, Saidi P: Methamphetamine intoxication—a speedy new treatment. Am J Med 64: 537–540, 1978.PubMedGoogle Scholar
  216. 216.
    Catravas JD, Waters IW, Hickenbottom JP, Davis WM: The effects of haloperidol, chlorpromazine and propranolol on amphetamine poisoning in the conscious dog. J Pharmacol Exp Ther 202: 230–243, 1977.PubMedGoogle Scholar
  217. 217.
    Davis WM, Logston DG, Hickenbottom JP: Antagonism of acute amphetamine intoxication by haloperidol and propranolol. Toxicol Appl Pharmacol 29: 397–403, 1974.PubMedGoogle Scholar
  218. 218.
    Wallace HE, Neumayen F, Gutch CE: Amphetamine poisoning and peritoneal dialysis. Am J Dis Child 108: 657–661, 1964.PubMedGoogle Scholar
  219. 219.
    Winchester JF, Gelfand MC, Knepshield JH, Schreiner GE: Dialysis and hemoperfusion of poisons and drugs—update. Trans Am Soc Artif Intern Organs 23: 762–842, 1977.PubMedGoogle Scholar
  220. 220.
    Gericke OL: Suicide by ingestion of amphetamine sulphate. JAMA 128: 1098–s1099, 1945.Google Scholar
  221. 221.
    Keiter WE, Arnold JH: Acute dexedrine intoxication in children. Arch Ped 72: 126–128, 1955.Google Scholar
  222. 222.
    Patuck D: Acute dextroamphetamine poisoning in a child. Br Med J 1: 670–671, 1956.PubMedGoogle Scholar
  223. 223.
    Ong BH: Dextroamphetamine poisonings. N Engl J Med 266: 1321–1322, 1962.PubMedGoogle Scholar
  224. 224.
    DiMaio VJM, Garriott JC: Death due to ingestion of dextroamphetamine. For Sci Gaz 8: 1–2, 1977.Google Scholar
  225. 225.
    Cravey RH, Baselt RC: Methamphetamine poisoning. J For Sci Soc 8: 118–120, 1968.Google Scholar
  226. 226.
    Zalis EG, Parmley LF Jr: Fatal amphetamine poisoning. Arch Intern Med 112: 822–826, 1963.PubMedGoogle Scholar
  227. 227.
    Cravey RH, Reed D: Intravenous amphetamine poisoning: report of three cases. J For Sci Soc 10: 109–112, 1970.Google Scholar
  228. 228.
    Hall CD, Blanton DE, Scatliff JH, Morris CE: Speed kills: fatality from the self-administration of methamphetamine intravenously. South Med J 66: 650–652, 1973.PubMedGoogle Scholar
  229. 229.
    Norheim G: A fatal case of phenmetrazine poisoning. J For Sci Soc 13: 287–289, 1973.Google Scholar
  230. 230.
    Hamer R, Phelps D: Inadvertent intra-arterial injection of (phenmetrazine)—a complication of drug abuse. Ann Emerg Med 10: 148–150, 1981.PubMedGoogle Scholar
  231. 231.
    Kendrick WC, Hull AR, Knochel JP: Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 86: 381–387, 1977.PubMedGoogle Scholar
  232. 232.
    Rubin RT: Acute psychotic reaction following ingestion of phentermine. J Psychiatr 120: 1124, 1964.Google Scholar
  233. 233.
    Pentel P: Toxicity of over-the-counter stimulants. JAMA 252: 1898–1903, 1984.PubMedGoogle Scholar
  234. 234.
    Dietz AJ: Amphetamine-like reactions to phenyl-propanolamine. JAMA 245: 601–602, 1981.PubMedGoogle Scholar
  235. 235.
    Mesnard B, Ginn DR: Excessive phenypropanolamine ingestion followed by subarachnoid hemorrhage. South Med J 77: 939, 1984.PubMedGoogle Scholar
  236. 236.
    Nakamura GR, Noguchi TT: Fatalities from cocaine overdoses in Los Angeles County. Clin Toxicol 18: 895–905, 1981.PubMedGoogle Scholar
  237. 237.
    Wetli CV, Mittleman RE: The “body packer” syndrome: toxocity following ingestion of illicit drugs packed for transportation. J For Sci 26: 492–500, 1981.Google Scholar
  238. 238.
    Coleman DL, Ross TF, Naughton JL: Myocardial ischemia and infarction related to recreational cocaine use. West J Med 136: 444–446, 1982.PubMedGoogle Scholar
  239. 239.
    Acker D, Sachs BP, Tracey KJ, Wise WE: Abruptio placentae associated with cocaine use. Am J Obstet Gynecol 146: 220–221, 1983.PubMedGoogle Scholar
  240. 240.
    Sharif JA: Renal infarction associated with intravenous cocaine use. Ann Emerg Med 13: 1145–1147, 1984.Google Scholar
  241. 241.
    Shesser R, Davis C, Edelstein S: Pneumomediastinum and pneumothorax after inhaling alkaloidal cocaine. Ann Emerg Med 10: 213–215, 1981.PubMedGoogle Scholar
  242. 242.
    Allred RJ, Ewer S: Fatal pulmonary edema following intravenous “free base” cocaine use. Ann Emerg Med 10: 441–442, 1981.PubMedGoogle Scholar
  243. 243.
    Sinner WN: The gastrointestinal tract as a vehicle for drug smuggling. Gastrointest Radiol 6: 319–323, 1981.PubMedGoogle Scholar
  244. 244.
    McCarron MM, Wood JD: The cocaine “body packer” syndrome—diagnosis and treatment. JAMA 250: 1417–1420, 1983.PubMedGoogle Scholar
  245. 245.
    Freed TA, Sweet LN, Gauder PJ: Balloon obturation bowel obstruction: a hazard of drug smuggling. Am J Roentgenol 127: 1033–1034, 1976.Google Scholar
  246. 246.
    Suarez CA, Arango A, Lester JL III: Cocaine-condom ingestion: Surgical treatment. JAMA 238: 1391–1392, 1977.PubMedGoogle Scholar
  247. 247.
    Bettinger J: Cocaine intoxication: massive oral overdose. Ann Emerg Med 9: 429–430, 1980.PubMedGoogle Scholar
  248. 248.
    Jonsson S, O’Meara M, Young JB: Acute cocaine poisoning. Am J Med 75: 1061–1064, 1983.PubMedGoogle Scholar
  249. 249.
    Orr D, Jones I: Anesthesia for laryngoscopy. A comparison of the cardiovascular effects of cocaine and lignocaine. Anaesthesia 23: 194–202, 1968.PubMedGoogle Scholar
  250. 250.
    Benchimol A, Bartall H, Desser KB: Accelerated ventricular rhythm and cocaine abuse. Ann Intern Med 88: 519–520, 1978.PubMedGoogle Scholar
  251. 251.
    Gay GR: Clinical management of acute and chronic cocaine poisoning Ann Emerg Med 11: 562–572, 1982.PubMedGoogle Scholar
  252. 252.
    Catravas JD, Waters IW, Walz MA, Davis WM: Antidotes for cocaine poisoning. New Engl J Med 297: 1238, 1977.PubMedGoogle Scholar
  253. 253.
    Bulletin of Poisindex, Drugdex, Emergindex Editorial Board: Yohimbine—an abused drug. Rocky Mountain Poison and Drug Center, Denver, Colorado, Apr, 1984.Google Scholar
  254. 254.
    Scatton B, Zivkovic B, Dedek J: Antidopaminergic properties of yohimbine. J Pharmacol Exp Ther 215: 494–499, 1980.PubMedGoogle Scholar
  255. 255.
    Boyd H, Chang V, Rand MJ: The anticholinesterase activity of some antiadrenaline agents. Br J Pharmacol 15: 525–531, 1960.Google Scholar
  256. 256.
    Freed WJ, Weinberger DR, Bing LA, Wyatt RJ: Neuropharmacological studies of phencylidine (PCP)-induced behavioral stimulation in mice. Psychopharmacology 71: 291–297, 1980.PubMedGoogle Scholar
  257. 257.
    Lambert GA, Lang WJ: Interaction between yohimbine alkaloids and amphetamine in mice. Psychopharmacology 51: 209–212, 1977.PubMedGoogle Scholar
  258. 258.
    Morales A, Surridge DHC, Marshall PG, Fenemore J: Nonhormonal pharmacological treatment of organic impotence. J Urol 128: 45–47, 1982.PubMedGoogle Scholar
  259. 259.
    Steers WD, McConnell J, Benson GS: Some pharmacologic effects of yohimbine on human and rabbit penis. Pharamcolog Rev 36: 799–802, 1984.Google Scholar
  260. 260.
    Sokolovsky M: Muscarinic receptors in the central nervous system. Int Rev Neurobiol 25: 139–183, 1984.PubMedGoogle Scholar
  261. 261.
    White P, Hiley CR, Goodhardt MJ, et al.: Neocortical cholinergic neurons in elderly people. Lancet 1: 668–670, 1977.PubMedGoogle Scholar
  262. 262.
    Longo VG: Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev 18: 965–996, 1966.PubMedGoogle Scholar
  263. 263.
    Gillick JS: Atropine toxicity in a neonate. Br J Anaesth 46: 793–794, 1974.PubMedGoogle Scholar
  264. 264.
    Mikolich JR, Paulson GW, Cross CJ: Acute anticholinergic syndrome due to jimson weed ingestion. Ann Intern Med 83: 321–325, 1975.PubMedGoogle Scholar
  265. 265.
    Hall RCW: Angel’s trumpet psychosis: a central nervous system anticholinergic syndrome. Am J Psychiatr 134: 312–314, 1977.PubMedGoogle Scholar
  266. 266.
    Information from manufacturer, O’Neal, Jones and Feldman Co.Google Scholar
  267. 267.
    Levy R: Arrhythmias following physostigmine administration in jimson weed poisoning. J Am Coll Emerg Phys 6: 107, 1977.Google Scholar
  268. 268.
    Gosselin RE, Gabourel JD, Wills JH: The fate of atropine in man. Clin Pharmacol Ther 1: 597–603, 1960.Google Scholar
  269. 269.
    Kaiser SC: The fate of atropine in man. Ann NY Acad Sci 179: 667–683, 1971.Google Scholar
  270. 270.
    Baker JP, Farley JD: Toxic psychosis following atopine eye drops. Br Med J 2: 1390–1392, 1958.PubMedGoogle Scholar
  271. 271.
    Hoefnagel D: Toxic effects of atropine and homatropine eyedrops in children. New Engl J Med 264: 168–171, 1961.PubMedGoogle Scholar
  272. 272.
    German E, Siddiqui N: Atropine toxicity from eyedrops. New Engl J Med 282: 689, 1970.PubMedGoogle Scholar
  273. 273.
    Hoffman GM, Gay JR: Atropine in an unusual case of poisoning. Pa Med 62: 1340–1341, 1959.Google Scholar
  274. 274.
    Beatson N: Atropine and paralytic ileus. Postgr Med J 58: 451–453, 1982.Google Scholar
  275. 275.
    Heath WE: Death from atropine poisoning. Br Med J 2: 608, 1950.PubMedGoogle Scholar
  276. 276.
    Comroe BI: Atropine poisoning: recovery after 71/2 grains of atropine sulphate by mouth. JAMA 101: 446–447, 1933.Google Scholar
  277. 277.
    Rubinstein JS: Abuse of antiparkinsonism drugs. JAMA 239: 2365–2366, 1978.PubMedGoogle Scholar
  278. 278.
    Pakes GE: Abuse of trihexyphenidyl. JAMA 240: 2434, 1978.PubMedGoogle Scholar
  279. 279.
    Craig DH, Rosen P: Abuse of antiparkinsonian drugs. Ann Emerg Med 10: 98–100, 1981.PubMedGoogle Scholar
  280. 280.
    Dollery CT, Davies DS, Draffan GH, et al.: Clinical pharmacology and pharmokinetics of Clonidine. Clin Pharm Ther 19: 11–17, 1976.Google Scholar
  281. 281.
    Davies DS, Wing LMH, Reid JL, et al.: Pharmokinetics and concentration-effect relationships of in¬travenous and oral Clonidine. Clin Pharm Ther 21: 593–601, 1977.Google Scholar
  282. 282.
    Kobinter W: Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 81: 40–100, 1978.Google Scholar
  283. 283.
    Isaac L: Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol 2(Suppl): S5–S19, 1980.Google Scholar
  284. 284.
    Wing LMH, Redi JL, Davies DS, et al.: Pharmacokinetic and concentration-effect relationships of Clonidine in essential hypertension. Eur J Clin Pharm 12: 463–469, 1977.Google Scholar
  285. 285.
    Hunyor SN, Bradstock K, Somerville PJ, et al.: Clonidine overdose. Br Med J 4: 23, 1975.PubMedGoogle Scholar
  286. 286.
    Stein B, Volans GN: Dixarit overdose: the problem of attractive tablets. Br Med J 2: 667–668, 1978.PubMedGoogle Scholar
  287. 287.
    Saperia J: Clonidine overdose. Br Med J 4: 580, 1975.PubMedGoogle Scholar
  288. 288.
    Poyner TF, Gennery BA, Vasey RH: Management in cases of Clonidine overdosage. Practitioner 217: 132–134, 1976.PubMedGoogle Scholar
  289. 289.
    Pai GA, Lipstiz DJ: Clonidine poisoning in children. Lancet 1: 1266–1267, 1977.Google Scholar
  290. 290.
    Moore MA, Phillipi P: Clonidine overdose. Lancet 2: 694, 1976.PubMedGoogle Scholar
  291. 291.
    Artman M, Boerth RC: Clonidine poisoning. Am J Dis Child 137: 171–174, 1983.PubMedGoogle Scholar
  292. 292.
    Mofenson HC, Greensher J, Weiss TE: Clonidine poisoning: is there a single antidote? Clin Toxicol 14: 271–275, 1979.PubMedGoogle Scholar
  293. 293.
    Anderson RJ, Hart GR, Crumpler CP, Lerman MJ: Clonidine overdose: report of six cases and review of the literature. Ann Emerg Med 10: 107–112, 1981.PubMedGoogle Scholar
  294. 294.
    Neuvonen PJ, Vilska J, Keranen A: Severe poisoning in a child caused by a small dose of Clonidine. Clin Toxicol 14: 369–374, 1979.PubMedGoogle Scholar
  295. 295.
    Olsson JM, Pruitt AW: Management of Clonidine ingestion in children. J Ped 103: 646–650, 1983.Google Scholar
  296. 296.
    Kulig K, Duffy J, Rumack BH, et al.: Naloxone for treatment of Clonidine overdose. JAMA 247: 1697, 1982.PubMedGoogle Scholar
  297. 297.
    Banner W, Lund ME, Clawson L: Failure of naloxone to reverse Clonidine toxic effect. Am J Dis Child 137: 1170–1171, 1983.PubMedGoogle Scholar
  298. 298.
    Rotellar JAO, Monasterio ES, Gene CG: Clonidine in thousand-fold overdose. Lancet 1: 1312, 1981.Google Scholar
  299. 299.
    Robertson D, Frölich JC, Carr RK, et al.: Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 298: 181–186, 1978.PubMedGoogle Scholar
  300. 300.
    Gilman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th Ed. Macmillan Publishing Co Inc, New York, 1980.Google Scholar
  301. 301.
    Katz AM, Repke DI, Haselbach W: Dependence of ionophore-and caffeine-induced calcium release from sarcoplasmic reticulum vesicles on external and internal calcium ion concentrations. J Biol Chem 252: 1938–1949, 1977.PubMedGoogle Scholar
  302. 302.
    Mitenko PA, Ogilvie RI: Rapidly achieved plasma concentration plateaus, with observations on theophylline kinetics. Clin Pharm Ther 13: 329–335, 1972.Google Scholar
  303. 303.
    Lillehei JP: Aminophylline—oral vs rectal administration. JAMA 205: 530–533, 1968.PubMedGoogle Scholar
  304. 304.
    Grygiel J, Birkett DJ: Effect of age on patterns of theophylline metabolism. Clin Pharm Ther 28: 456–462, 1980.Google Scholar
  305. 305.
    Bukowskyj M, Nakatsu K, Munt PW: Theophylline reassessed. Ann Intern Med 101: 63–73, 1984.PubMedGoogle Scholar
  306. 306.
    Nakada T, Kwee IL, Lerner AM, Remler MP: Theophylline-induced seizures: clinical and pathological aspects. West J Med 138: 371–374, 1983.PubMedGoogle Scholar
  307. 307.
    Vincent FM: Fatal theophylline-induced seizures. Postgr Med J 6: 76–77, 1978.Google Scholar
  308. 308.
    Winke CL, Bricker JD, Collom WD, Fochtman FW: Theophylline fatalities. For Sci Int 15: 233–236, 1980.Google Scholar
  309. 309.
    Anderson JR, Poklis A, Slavin RG: A fatal case of theophylline intoxication. Arch Intern Med 143: 559–560, 1983.PubMedGoogle Scholar
  310. 310.
    Park GD, Spector R, Roberts RJ, et al.: Use of hemoperfusion for treatment of theophylline intoxication. Am J Med 74: 961–966, 1983.PubMedGoogle Scholar
  311. 311.
    Addiction Research Foundation of Ontario: Facts about caffeine. Toronto, Canada, Jan 1981.Google Scholar
  312. 312.
    Turner JE, Cravey RH: A fatal ingestion of caffeine. Clin Toxicol 10: 341–344, 1977.PubMedGoogle Scholar
  313. 313.
    Sullivan JL: Caffeine poisoning in an infant. J Ped 90: 1022–1023, 1977.Google Scholar
  314. 314.
    Boyd EM: The acute oral toxicity of caffeine. Toxicol Appl Pharmacol 1: 250–257, 1959.Google Scholar
  315. 315.
    May DC, Long T, Madden R, et al.: Caffeine toxicity secondary to street drug ingestion. Ann Emerg Med 10: 549, 1981.PubMedGoogle Scholar
  316. 316.
    Benowitz NL, Osterloh J, Goldschlager N, et al.: Massive catecholamine release from caffeine poisoning. JAMA 248: 1097–1098, 1982.PubMedGoogle Scholar
  317. 317.
    Bernstein E, Diskant BM: Phenylpropanolamine: a potentially hazardous drug. Ann Emerg Med 11: 311–315, 1982.PubMedGoogle Scholar
  318. 318.
    Swenson RD, Golper TA, Bennett WM: Acute renal failure and rhabdomyolysis after ingestion of phenylpropanolamine-containing diet pills. JAMA 248: 1216, 1982.PubMedGoogle Scholar
  319. 319.
    Howrie DL, Wolfson JH: Phenylpropanolamine- induced hypertensive seizures. J Ped 102: 143–145, 1983.Google Scholar
  320. 320.
    Bale JF, Fountain T, Shaddy R: Phenylpropanola- mine-associated CNS complications in children and adolescents. Am J Dis Child 138: 683–685, 1984.PubMedGoogle Scholar
  321. 321.
    Weesner KM, Denison M, Roberts RJ: Cardiac arrhythmias in an adolescent following ingestion of an over-the-counter stimulant. Clin Ped 21: 700–701, 1982.Google Scholar
  322. 322.
    Heath A: Beta-adrenoceptor blocker toxicity: clinical features and therapy. Am J Emerg Med 2: 518–525, 1984.PubMedGoogle Scholar
  323. 323.
    Glick G, Parmly WW, Wecksler AS, et al.: Glucagon: its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta receptor blockade with propranolol. Circ Res 22: 789–799, 1968.PubMedGoogle Scholar
  324. 324.
    Illingworth RN: Glucagon for beta-blocker poisoning. Practitioner 223: 683, 1979.PubMedGoogle Scholar
  325. 325.
    Rosa RM, Silva P, Young JB, Landsberg L, et al.: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302: 431, 1980.PubMedGoogle Scholar
  326. 326.
    Information from manufacturer, Stuart Company.Google Scholar
  327. 327.
    Kirch W, Koehler H, Mutschier E, Schaefer M: Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharm 19: 65–71, 1981.Google Scholar
  328. 328.
    Shanahan FLJ, Counihan TB: Atenolol self poisoning. Br Med J 2: 773, 1978.PubMedGoogle Scholar
  329. 329.
    Moller BHJ: Massive intoxication with metoprolol. Br Med J 24: 222, 1976.Google Scholar
  330. 330.
    Stajic M, Granger RH, Beyer JC: Fatal metoprolol overdose. J Analyt Toxicol 8: 228–230, 1984.Google Scholar
  331. 331.
    Sire S: Metoprolol intoxication. Lancet 2: 1137, 1976.PubMedGoogle Scholar
  332. 332.
    Shore ET, Cepin D, Davidson MJ: Metoprolol overdose. Ann Emerg Med 10: 524–527, 1981.PubMedGoogle Scholar
  333. 333.
    Holzbecker M, Perry RA, Ellenberger HA: Report of a metoprolol associated death. J For Sci 27: 715–717, 1982.Google Scholar
  334. 334.
    Information from manufacturer, Sandoz Pharmaceuticals, 1984.Google Scholar
  335. 335.
    Wermut W, Wojcicki M: Suicidal attempt with propranolol. Br Med J 3: 591, 1973.PubMedGoogle Scholar
  336. 336.
    Turner JE, Cravey RH: A fatal case involving propranolol and codeine. Clin Toxicol 8: 271–275, 1975.PubMedGoogle Scholar
  337. 337.
    Gault R, Monforte JR, Khasnabis S: A death involving propranol (Inderal). Clin Toxicol 11: 295–299, 1977.PubMedGoogle Scholar
  338. 338.
    Kristinsson J, Johnannesson J: A case of fatal propranolol intoxication. Acta Pharm Tox 41: 190–192, 1977.PubMedGoogle Scholar
  339. 339.
    Information from manufacturer, Merck Company, 1984.Google Scholar
  340. 340.
    Elliott J: Consensus on amantadine use in influenza A [Medical News] JAMA 242: 2383–2387, 1979.PubMedGoogle Scholar
  341. 341.
    Grelak RP, Clark R, Stump JM, et al.: Amantadine-dopamine interaction: possible mode of action in parkinsonism. Science 169: 203–204, 1970.PubMedGoogle Scholar
  342. 342.
    Information from manufacturer, Du Pont Company, 1984.Google Scholar
  343. 343.
    Ing TS, Rahn AC, Armbruster KFW, et al.: Accumulation of amantadine hydrochloride in renal insufficiency. N Engl J Med 291: 1257, 1974.PubMedGoogle Scholar
  344. 344.
    Fahn S, Craddock G, Kumin G: Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 25: 45–48, 1971.PubMedGoogle Scholar
  345. 345.
    Sartori M, Pratt CM, Young JB: Torsade de Pointe—malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 77: 388–391, 1984.PubMedGoogle Scholar
  346. 346.
    Casey DE: Amantadine intoxication reversed by physostigmine. New Engl J Med 298: 516, 1978.PubMedGoogle Scholar
  347. 347.
    Berkowitz CD: Treatment of acute amantadine toxicity with physostigmine. J Ped 95: 144–145, 1979.Google Scholar
  348. 348.
    Green JP, Johnson CL, Weinstein H: Histamine as a neurotransmitter. In Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: a generation of progress. Raven Press, New York, pp 319–332, 1978.Google Scholar
  349. 349.
    Schwartz JC: Histaminergic mechanisms in brain. Ann Rev Pharmacol Toxicol 17: 325–339, 1977.Google Scholar
  350. 350.
    Information from manufacturer, Parke-Davis Company, 1984.Google Scholar
  351. 351.
    Information from manufacturer, Smith Kline Company, 1984.Google Scholar
  352. 352.
    Shaw RG, Mashford ML, Desmond PV: Cardiac arrest after intravenous injection of Cimetidine. Med J Austral 2: 629–630, 1980.PubMedGoogle Scholar
  353. 353.
    King AR: Cardiac arrest and Cimetidine. Med J Austral 1: 139, 1981.PubMedGoogle Scholar
  354. 354.
    Kato H, Kurihara J, Kasuya Y: Cardiovascular effects of Cimetidine. Arch Intern Pharmacodyn 249: 247–256, 1981.Google Scholar
  355. 355.
    Hiss J, Hepler BR, Falkowski A J, Sunshine I: Fatal bradycardia after intentional overdose of cimeti- dine and diazepam. Lancet 2: 982, 1982.PubMedGoogle Scholar
  356. 356.
    Pizzella LM, Moore MC, Schulz RW, et al.: Removal of cimetidine by peritoneal dialysis, hemodialysis and charcoal hemoperfusion. Ther Drug Mon 2: 273–281, 1980.Google Scholar
  357. 357.
    Pahnke WN, Jurland AA, Unger S, Savage C, Grof S: The experimental use of psychedelic (LSD) psychotherapy. JAMA 212: 1856–1863, 1970.PubMedGoogle Scholar
  358. 358.
    Gilman AG, Goodman LS, Gilman A (eds): The pharmacological basis of therapeutics, 6th ed. Macmillan Publishing Co Inc, New York, 1980.Google Scholar
  359. 359.
    Gosslin RE, Hodge HC, Smith RP, Gleason MN: Clinical toxicology of commercial products, 4th ed. Williams and Wilkins Co, Baltimore, 1976.Google Scholar
  360. 360.
    Feldberg W: The monoamines of the hypothalamus as mediators of temperature responses. In Robson JM, Stacey RS (eds): Recent advances in pharmacology, 4th ed. J & A Churchill, Ltd, London, 1968.Google Scholar
  361. 361.
    Feldberg W, Sherwood SL: Injections of drugs into the lateral ventricle of the cat. J Physiol (London) 123: 148–167, 1954.Google Scholar
  362. 362.
    Born GVR, Michal F: 5-Hydroxytryptamine receptors on platelets. Biochemistry and pharmacology of platelets. Ciba Symposium, vol 35. Amsterdam, 1975.Google Scholar
  363. 363.
    Schwarz BE, Bickford RB: Reversibility of induced psychosis with chlorpromazine. Proc Staff Meet Mayo Clin 30: 407–417, 1955.PubMedGoogle Scholar
  364. 364.
    Solursh LP, Clement WR: Use of diazepam in hallucinogenic drug crises. JAMA 205: 98–99, 1968.Google Scholar
  365. 365.
    Horowitz MJ: Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatr 126: 565–569, 1969.PubMedGoogle Scholar
  366. 366.
    Friedman SA, Hirsch SE: Extreme hyperthermia after LSD ingestion. JAMA 217: 1549–1550, 1971.PubMedGoogle Scholar
  367. 367.
    Klock JC, Boerner U, Becker CE: Coma, hyperthermia and bleeding associated with massive LSD overdose. West J Med 120: 183–188, 1974.PubMedGoogle Scholar
  368. 368.
    Ingram AL: Morning glory seed reaction. JAMA 190: 1133–1134, 1964.PubMedGoogle Scholar
  369. 369.
    Cohen S: Suicide after ingestion of morning glory seeds. Am J Psychiatr 120: 1024–1025, 1964.PubMedGoogle Scholar
  370. 370.
    Fink PJ, Goldman MJ, Lyons I: Morning glory seed psychosis. Arch Gen Psychiatr 15: 209, 1966.Google Scholar
  371. 371.
    Dewhurst K: Psilocybin intoxication. Br J Psych 137: 303–304, 1980.Google Scholar
  372. 372.
    Young RE, Milroy R, Hutchinson S, Keeson CM: The rising price of mushrooms. Lancet 1: 213–214, 1982.PubMedGoogle Scholar
  373. 373.
    Snyder SH, Faillace L, Hollister L. 2,5-dimethoxy- 4-methyl-amphetamine (STP): a new hallucinogenic drug. Science 158: 669–670, 1967.PubMedGoogle Scholar
  374. 374.
    Smith DE: The psychotomimetic amphetamines with special reference to STP (DOM) toxicity. J Psychedel Drugs 2: 75–85, 1969.Google Scholar
  375. 375.
    Richard KC, Borgstedt HH: Near fatal reaction to ingestion of the hallucinogenic drug MDA. JAMA 218: 1826–1827, 1971.Google Scholar
  376. 376.
    Finkle BS: MDA death. Bull Int Assoc For Toxicol 6: 4, 1969.Google Scholar
  377. 377.
    Cimbura G: 3,4-methylenedioxyamphetamine (MDA); analytical and forensic aspects of fatal poisoning. J For Sci 17:329, 1972.Google Scholar
  378. 378.
    Reed D, Cravey RH, Sedgwick PR: A fatal case involving methylenedioxyamphetamine. Clin Toxicol 5: 3, 1972.PubMedGoogle Scholar
  379. 379.
    Lukaszewski T: 3,4-Methylenedioxyamphetamine overdose. Clin Toxicol 15:405–409, 1979.Google Scholar
  380. 380.
    Poklis A, Mackell MA, Drake WK: Fatal intoxica-tion from 3,4- methylenedioxyamphetamine. J For Sci 24: 70, 1979.Google Scholar
  381. 381.
    Simpson DL, Rumack BH: Methylenedioxyamphetamine: clinical description of overdose, death, and review of pharmacology. Arch Intern Med 141: 1507, 1981.PubMedGoogle Scholar
  382. 382.
    Cimbura G: PMA deaths in Ontario. Can Med Assoc J 110: 1263–1264, 1974.PubMedGoogle Scholar
  383. 383.
    Shulgin AT: Chemistry of phenethylamines related to mescaline. J Psychedel Drugs 11: 41, 1979.Google Scholar
  384. 384.
    Ludwig AM, Levine J: Patterns of hallucinogenic drug abuse. JAMA 191: 104–108, 1965.Google Scholar
  385. 385.
    Teitelbaum DT, Wingeleth DC: Diagnosis and management of recreational mescaline self poisoning. J Analyt Toxicol 1: 36–37, 1977.Google Scholar
  386. 386.
    Speck LB: Toxicity and effects of increasing doses of mescaline. J Pharm Exper Ther 119: 78–84, 1957.Google Scholar
  387. 387.
    Forrest JE, Heacock RA: Nutmeg and mace, the psychotropic spices from Myristica fragrans. Lloydia 35: 440–449, 1972.PubMedGoogle Scholar
  388. 388.
    Payne RB: Nutmeg intoxication. N Engl J Med 269: 36, 1963.PubMedGoogle Scholar
  389. 389.
    Celesia G, Messert B, Murphy M: Status epilepticus of late onset. Neurology 22: 1047, 1972.PubMedGoogle Scholar
  390. 390.
    Kim CH, Perlstein MA: Encephalitis with catatonic schizophrenic symptoms. Illin Med J 138: 503–507, 1970.Google Scholar
  391. 391.
    Penn H, Racy J, Lapham L, et al.: Catatonic behavior, viral encephalopathy, and death. Arch Gen Psychiatr 27: 758–761, 1972.PubMedGoogle Scholar
  392. 392.
    Jaffe N: Catatonia and hepatic dysfunction. Dis Ner Syst 28: 606–608, 1967.Google Scholar
  393. 393.
    Hanson GD, Brown MJ: Waxy flexibility in a post-partum woman: a case report and review of the catatonic syndrome. Psychiatr Q 47: 95–103, 1973.PubMedGoogle Scholar
  394. 394.
    Thompson GN: Cerebral lesions simulating schizophrenia: three case reports. Biolog Psychiatr 3: 59–64, 1970.Google Scholar
  395. 395.
    Micheels LJ: Catatonic syndrome in a case of sub-dural hematoma. J Nerv Ment Dis 117: 123–129, 1953.PubMedGoogle Scholar
  396. 396.
    Hermann M, Harpham D, Rosenblum M: Non- schizophrenic catatonic states. NY State J Med 42: 624, 1942.Google Scholar
  397. 397.
    Belfer ML, d’Autremont C: Catatonia-like symptomatology. Arch Gen Psychiatr 24: 119–120, 1971.PubMedGoogle Scholar
  398. 398.
    Murphy JP, Neuman MA: Fatal cerebral vascular accident associated with catatonic schizophrenia. Arch Neurol Psychiatr 49: 724, 1943.Google Scholar
  399. 399.
    Malamud N, Boyd D: Sudden “brain death” in schizophrenia with extensive lesions in the cerebral cortex. Arch Neurol Psychiatr 41: 352–364, 1939.Google Scholar
  400. 400.
    Hockaday TD, Keynes WM, McKenzie JK: Catatonic stupor in elderly woman with hyperparathy-roidism. Br Med J 5479: 85–87, 1966.Google Scholar
  401. 401.
    Lake CR, Fann WE: Possible potentiation of haloperidol neurotoxicity in acute hyperthyroidism. Br J Psych 123: 523–525, 1973.Google Scholar
  402. 402.
    Katz SE: A catatonic syndrome associated with diabetes mellitus. Arch Neurol Psychiatr 31: 880, 1934.Google Scholar
  403. 403.
    Schwab J, Barrow MV: A reaction to organic fluo-rides simulating classical catatonia. Am J Psychiatr 120: 1196–1197, 1964.PubMedGoogle Scholar
  404. 404.
    Gelenberg A J, Mandel MR: Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatr 34: 947–950, 1977.PubMedGoogle Scholar
  405. 405.
    McCarron MM, Schulze BW, Thompson GA, et al.: Acute phencyclidine intoxication: clinical patterns, complications and treatment. Ann Emerg Med 10: 290–297, 1981.PubMedGoogle Scholar
  406. 406.
    CarofF SN: The neuroleptic malignant syndrome. J Clin Psychiatr 41: 79–83, 1980.Google Scholar
  407. 407.
    Simpson DM, Davis GC: Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatr 141: 796–797, 1984.PubMedGoogle Scholar
  408. 408.
    Eles GR, Songer JE, DiPette DJ: Neuroleptic malignant syndrome complicated by disseminated in-travascular coagulation. Arch Intern Med 144: 1296–1297, 1984.PubMedGoogle Scholar
  409. 409.
    Hashimoto F, Sherman CB, Jeffery WH: Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intern Med 144: 629–630, 1984.PubMedGoogle Scholar
  410. 410.
    Coons DJ, Hillman FJ, Marshall RW: Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatr 139: 944–945, 1982.PubMedGoogle Scholar
  411. 411.
    Goekoop JG, Carbaat PA: Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 2: 49–50, 1982.PubMedGoogle Scholar
  412. 412.
    May DC, Morris SW, Stewart RM, et al.: Neuroleptic malignant syndrome: response to dantrolene sodium. Ann Intern Med 98: 183–184, 1983.PubMedGoogle Scholar
  413. 413.
    McCarron MM, Boettger ML, Peck JJ: A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatr 43: 381–382, 1982.Google Scholar
  414. 414.
    Amdurski S, Radwin M, Levi A, Elizur A: A therapeutic trial of amantadine in haloperidol-induced malignant neuroleptic syndrome. Curr Ther Res 33: 225–229, 1983.Google Scholar
  415. 415.
    Mueller PS, Vester JW, Fermaglieli J: Neuroleptic malignant syndrome—successful treatment with bromocriptine. JAMA 249: 386–388, 1983.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1986

Authors and Affiliations

  • Margaret M. McCarron

There are no affiliations available

Personalised recommendations